ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO115

Plasma Humanin Level in AKI and CKD Patients

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Cai, Wenjing, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
  • Wu, Min, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
  • Shi, Qingying, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
  • Fu, Xinyi, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
  • Lei, Chenyu, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
  • Chen, Yuanhan, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
  • Ye, Zhiming, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
  • Liang, Xinling, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
  • Li, Zhilian, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Background

Humanin is a mitochondrial-derived cytoprotective peptide that reflects mitochondrial damage.Its level in the plasma of patients with AKI and CKD has not been reported yet. We aimed to determine the diagnostic value of humanin for kidney injury.

Methods

A total of 188 patients with kidney disease and 32 healthy controls were collected, patients with kidney disease were divided into AKI group (n=54) and CKD group (n=134) according to KDIGO definition. The plasma humanin level of each group was detected by enzyme-linked immunosorbent assay. ROC curves were used to analyze the diagnostic performance of humanin for AKI and CKD.

Results

A total of 188 patients (54 AKI, 134 CKD) and 32 healthy people were studied. The plasma humanin level in the AKI group and the CKD group was significantly higher than that in the healthy control group [576.5 (430.0-796.2) pg/mL vs 298.6 (188.8-366.4) pg/mL, p=0.0006 and 325.9 (207.3-631.4) pg/mL vs 298.6 (188.8-366.4) pg/mL, p=0.0164, respectively]. On the basis of receiver-operating characteristic analysis humanin could predict AKI and CKD [area under the curve (95% confidence interval) 0.869 (0.794-0.944) and 0.620 (0.529-0.711), respectively]. A cut-off point >413.2 pg/mL for humanin had a sensitivity of 0.78 and specificity of 0.91 in predicting AKI and a cut-off point >481.4 pg/mL for humanin had a sensitivity of 0.38 and specificity of 0.89 in predicting CKD.

Conclusion

Humanin is expressed in patients with AKI and CKD and may be a novel biomarker in response to kidney damage.

Funding

  • Government Support – Non-U.S.